ValenzaBio Revenue and Competitors
Estimated Revenue & Valuation
- ValenzaBio's estimated annual revenue is currently $465k per year.
- ValenzaBio's estimated revenue per employee is $77,500
- ValenzaBio's total funding is $93.9M.
Employee Data
- ValenzaBio has 6 Employees.
- ValenzaBio grew their employee count by -45% last year.
ValenzaBio's People
| Name | Title | Email/Phone |
|---|
ValenzaBio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is ValenzaBio?
$93.9M
Total Funding
6
Number of Employees
$465k
Revenue (est)
-45%
Employee Growth %
N/A
Valuation
N/A
Accelerator
ValenzaBio News
2022-03-30 - ValenzaBio Announces FDA Clearance of Investigational New ...
ValenzaBio Announces FDA Clearance of Investigational New Drug Application for VB421, an Anti-IGF-1R Monoclonal Antibody for the Treatment...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.4M | 6 | N/A | N/A |
#2 | $0.4M | 6 | N/A | N/A |
#3 | $0.4M | 6 | N/A | N/A |
#4 | $0.4M | 6 | N/A | N/A |
#5 | $0.4M | 6 | N/A | N/A |